Sun Pharma gets Brazil nod for Semaglutide
Sun Pharma has received regulatory approval in Brazil to manufacture and market generic semaglutide for type 2 diabetes. This expansion follows the company's recent launch of the drug in South Africa and India.
Why it matters
The entry of generic semaglutide into the Brazilian market increases access to affordable diabetes treatments and impacts the competitive landscape for weight-loss and diabetes drugs.
Sun Pharmaceutical Industries has received Brazilian Health Regulatory Agency ANVISA approval to manufacture and market semaglutide injection in the Latin American country.
The generic drugmaker plans to launch the product in the next few days in partnership with Hypera Pharma, a pharmaceutical company in Brazil. It will be available as a pre‑filled, multi‑dose injectable pen in two strengths (2 mg/1.5 mL and 4 mg/3 mL) allowing flexible, once‑weekly dosing.
“The approval of semaglutide in Brazil expands access to an evidence-based treatment option for people living with inadequately controlled type 2 diabetes. It reflects the strength of our development and manufacturing capabilities,” said Aalok Shanghvi, Chief Operating Officer, Sun Pharma.
The semaglutide injectable market in Brazil is around $413 million, Sun Pharma said citing IQVIA, MAT June 2026 data.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in